ArticleFrontiers in immunology2025
Monoclonal gammopathy-associated C3 glomerulonephritis secondary to follicular lymphoma: a case report.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C3 glomerulopathy encompasses a group of glomerular diseases characterized by the predominant deposition of complement component C3 on kidney biopsy without significant immunoglobulin staining. Monoclonal gammopathy (MIg)-associated C3 glomerulopathy is considered a distinct subtype. We report a case of a 38-year-old male with a history of HBV infection who presented with a left neck mass, hematuria, proteinuria, elevated creatinine, normal complement level, and an IgM kappa M-spike on serum immunofixation electrophoresis. He was diagnosed with follicular lymphoma-associated MIg-C3 glomerulonephritis (MIg-C3GN), accompanied by extensive infiltration of lymphoma cells in the renal interstitium. Kidney immunohistochemistry was positive for CD19 and CD20 (B-cell markers), as well as CD10 and Bcl2, confirming the follicular lymphoma subtype. Within the areas of lymphoma cell infiltration, immunohistochemistry was also positive for IgM and kappa light chains but negative for lambda light chains, consistent with the serum electrophoresis findings. Positive autoantibodies to complement C3 convertase and complement factor H indicated complement dysregulation. The patient successively underwent various chemotherapy and targeted therapy regimens. During nearly 2 years of follow-up, renal outcomes were favorable, with resolution of hematuria and proteinuria and normalization of renal function, suggesting that lymphoma-directed therapy can improve renal outcomes in MIg-C3GN. However, the patient achieved partial remission but later relapsed and progressed, with suspicion of transformation into diffuse large B-cell lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.